2 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow NaCl (0,9%): new trials by email Literature Review of NaCl (0,9%) trials Research Report on NaCl (0,9%)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders ILT-101 ld-(IL2), NaCl (0,9%) - Autism Spectrum Disorder | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 22 | 2026-10-01 | 2026-05-15 |
| Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial Methylprednisolone 250 mg, NaCl (0,9%) - STEMI - ST Elevation Myocardial Infarction | Phase 3 | Recruiting | Thomas Engstrom | 5204 | 2026-04-20 | 2026-04-23 |
| Remimazolam for Emergence Delirium Prevention in Children Undergoing Tonsillectomy Remimazolam 20 MG Injection [Byfavo], NaCl (0,9%) - Remimazolam, Tonsillectomy | Phase 1 | Completed | University Hospital of Split | 110 | 2024-04-01 | 2026-07-15 |
| Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency ferric carboxymaltose, NaCl (0,9%) - Type 2 Diabetes Mellitus, Iron Deficiency | Phase 3 | Completed | GWT-TUD GmbH | 152 | 2012-08-01 | 2021-02-04 |
Autism Spectrum Disorder (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Emergence Delirium (1) · Iron Deficiencies (1) · ST Elevation Myocardial Infarction (1)
Assistance Publique - Hôpitaux de Paris (1) · GWT-TUD GmbH (1) · Thomas Engstrom (1) · University Hospital of Split (1)
Croatia (1) · Denmark (1) · France (1) · Germany (1)
Christoph Schindler, MD (1) · Filip Peris (1)
2025 (2)